IVTCC 2.0: a Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Aug 17, 2020
Trial Information
Current as of October 15, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an international, observational registry called IVTCC 2.0. It follows people who are having catheter ablation to treat ventricular tachycardia (a fast, potentially dangerous heart rhythm) or premature ventricular contractions (extra heartbeats). The goal is to collect real-world data to see how well ablation works over time and to learn about safety and long-term outcomes, not to test a new drug or device. Results are not yet available.
Who can join and what to expect: the registry includes both adults and children who are undergoing catheter ablation for VT or PVC at about 30 participating centers around the world. All eligible patients are considered; enrollment is by invitation. Participants will have data collected about their procedure and follow-up for up to 10 years, with a focus on the main outcome—whether VT episodes requiring a shock from an implantable device or a repeat procedure continue or stop—and secondary outcomes like major complications within 12 months and time to transplant or death over 10 years. This study aims to better understand ablation outcomes and improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All patients undergoing catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs).
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Charleston, South Carolina, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Los Angeles, California, United States
Houston, Texas, United States
Aurora, Colorado, United States
Seattle, Washington, United States
Bronx, New York, United States
Sacramento, California, United States
Baltimore, Maryland, United States
San Francisco, California, United States
Chicago, Illinois, United States
Portland, Oregon, United States
Rochester, Minnesota, United States
Boston, Massachusetts, United States
Charlottesville, Virginia, United States
Nashville, Tennessee, United States
Philadelphia, Pennsylvania, United States
Rotterdam, Netherlands
Milan, Italy
Jerusalem, Israel
Leiden, Netherlands
New York, New York, United States
Saint Louis, Missouri, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Worcester, Massachusetts, United States
New York, New York, United States
York, Pennsylvania, United States
Gainesville, Florida, United States
Salt Lake City, Utah, United States
Hartford, Connecticut, United States
Phoenix, Arizona, United States
Kansas City, Kansas, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Austin, Texas, United States
Montréal, Canada
Milan, Italy
Koshigaya, Japan
Madrid, Spain
Wandsworth, United Kingdom
Patients applied
Trial Officials
Jason Bradfield, MD
Principal Investigator
University of California, Los Angeles
Kalyanam Shivkumar, MD, PhD
Study Chair
University of California, Los Angeles
Paolo Della Bella, MD
Study Chair
San Raffaele Hospital, Italy
Francis Marchlinski, MD, FACC, FAHA, FHRS
Study Chair
University of Pennsylvania Health System
Andrea Natale, MD, FACC, FHRS, FESC
Study Chair
Texas Cardiac Arrhythmia Institute at St. David's Medical Center
William G Stevenson, MD
Study Chair
Vanderbilt Heart and Vascular Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials